

FIRST QUARTER HIGHLIGHTS

- Immunotec announces positive First-Quarter results and the return to profitability
- EBITDA at \$737,000 or 7% of total revenues
- Cash position at \$2.3 million
- Active distributors up 8% to 27,000
- Entered new markets: France, Germany, and the Caribbean

A WORD FROM THE PRESIDENT & CEO

A return to profitability after a challenging 2009 is a demonstration that our reorganized business model is starting to create shareholder value. Our message on *Health Improvement and Income Opportunity* seems well received by our distributors to establish us as a first class multi-level marketing company.



James A. Northrop
President & CEO

FINANCIAL HIGHLIGHTS – Q1 2010

(in millions of Canadian dollars, except per share data)

For the three month period ended
January 31,
(unaudited)

	Q1-2010 \$	Q2-2009 \$
Network Sales	8,865,644	9,234,866
Other Revenue	1,615,426	1,456,643
	10,481,070	10,691,509
Earnings (loss) from continuing operations	450,469	(238,630)
EPS (diluted)	0.005	(0.003)
EBITDA before discontinued operations	737,000	4
As a % of revenues	7.0%	0.0%

3-YEAR FINANCIAL REVIEW

(in millions of Canadian dollars, except per share data)

	2009	2008	2007
REVENUES			
Network Sales	37.9	36.0	31.3
Other Revenues	6.8	6.3	4.7
	44.7	38.1	36.0
Margin before expenses	12.3	13.1	12.7
EBITDA	(0.6)	2.6	2.4
EBITDA margin	(1.3%)	6.8%	6.0%
Loss (earnings) from continuing operations	(2.7)	0.9	0.9
EPS	(0.038)	0.013	0.013

ABOUT IMMUNOTEC INC.


Immunotec is a leader in the immune segment of the Health and Wellness category, and markets a wide variety of natural dietary supplements. The company's patented flagship product Immunocal is scientifically proven and medically acknowledged to optimize the human immune system, and is supported by a comprehensive line of proprietary vitamins, minerals, and other health related products.

At the end of the first quarter of 2010, the Company's global network was comprised of 27,000 distributors. In contrast to the retail channel of product distribution, Immunotec's direct-selling model allows for the strict control of variable selling costs and provides superior long term margin opportunities. Management has determined that for Immunotec's product portfolio network marketing is the most effective business model to build recurrent cash flow and value for shareholders.


Headquartered with manufacturing facilities near Montreal, Canada, the Company also subcontracts certain distribution logistics and capacity to support its activities in the United States, Europe, and the Caribbean.

GEOGRAPHIC DISTRIBUTION

(in % of Q1 sales)



STOCK PERFORMANCE



IMMUNOTEC INC.

300 Joseph Carrier
Vaudreuil-Dorion, Québec
J7V 5V5
www.immunotec.com

INVESTOR RELATIONS

Patrick Montpetit
Chief Financial Officer
Tel.: (450) 510-4527
Fax: (450) 424-9993

STOCK INFORMATION

TSX Venture Exchange Symbol: IMM
Price: \$0.36
52 week High/Low: \$0.60 - \$0.25
Fully diluted shares: 70.0 MM
Market capitalization: \$25.2 MM